Navigation Links
Novavax Announces Poster Presentation at the 47th Annual Meeting of the IDSA
Date:10/29/2009

ROCKVILLE, Md., Oct.29 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that its abstract has been selected for poster presentation at the Infectious Diseases Society of America (IDSA) 47th Annual meeting being held in Philadelphia, Pennsylvania from October 29 - November 1, 2009.

Poster presentation: "Safety and Immunogenicity of a Recombinant Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Healthy Adults", Penny Heaton, M.D., Maria Allende, M.D., Kathy Lenhard, R.N., Mike Massare, PhD., and Mark Wolff, PhD. Saturday October 31, 2009 12:30 pm to 2:00 pm., Pennsylvania Convention Center, Poster Hall A.

About the 47th Annual Meeting of the IDSA

This conference will showcase abstract presentations containing outstanding, noteworthy science; and expanded roster of challenging interactive sessions; symposia on management of difficult pathogens, such as MRSA, Clostridium difficle, and drug-resistant mycobacteria, gram-negative bacillia and fungi; and the promises and challenges of new vaccines. The Special Plenary Session and Named Lectures will highlight important advancements as well as challenges in the world of infectious diseases. Additional information is available at www.idsociety.org.

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP -based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The Company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com

SOURCE Novavax, Inc.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Novavax CEO to Present at BIO CEO & Investor Conference
2. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
3. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
4. Novavax CEO to Present at the World Vaccine Congress 2008
5. Novavax Opens Its First U.S. Vaccine Plant
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. Novavax Reports First Quarter 2008 Financial Results
8. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
9. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
10. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
11. Novavax to Join Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... ... April 18, 2017 , ... Optofluidics today announced that ... after the company changed focus to making analytical tools for biopharmaceutical quality control. ... technology,” says CEO Robert Hart. Founders Bernardo Cordovez, Robert Hart and David Erickson ...
(Date:4/19/2017)... ... April 19, 2017 , ... WHO: Peggy Lillis ... through education and advocacy. Founded in 2010 in memory of a single-parent mom ... foundation has become the most-consulted source for patient-focused information on C. diff infections ...
(Date:4/19/2017)... Calif. , April 19, 2017  As ... Drug Abuse and Heroin Summit ,  Proove® Biosciences, ... study analyzing genetics, environmental, and lifestyle factors to ... from the University of Southern California (USC), the ... , and Proove publish results showing that Proove ...
(Date:4/19/2017)... Mass. , April 19, 2017   ... results from the multi-center Procalcitonin MOnitoring SEpsis (MOSES) ... print issue of Critical Care Medicine . ... Mortality in Severe Sepsis Patients: Results From the ... use of the B·R·A·H·M·S PCT (procalcitonin) assay to ...
Breaking Biology Technology:
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/5/2017)... YORK , April 5, 2017 Today ... is announcing that the server component of the HYPR ... known for providing the end-to-end security architecture that empowers ... HYPR has already secured over 15 million ... makers including manufacturers of connected home product suites and ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):